{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:54:14Z","timestamp":1790463254251,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2\u20133\/100,000\/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.<\/jats:p>","DOI":"10.3390\/cancers13153745","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T09:25:52Z","timestamp":1627291552000},"page":"3745","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma"],"prefix":"10.3390","volume":"13","author":[{"given":"H\u00e9l\u00e8ne","family":"Vellemans","sequence":"first","affiliation":[{"name":"Department of Hematology, CHU UCL, 530 Yvoir, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P. E.","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology, CHU UCL, 530 Yvoir, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1097\/HS9.0000000000000149","article-title":"Controversies in the treatment of classical Hodgkin lymphoma","volume":"2","author":"Eichenauer","year":"2018","journal-title":"Hemasphere"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","article-title":"Optimizing therapy in advanced stage Hodgkin lymphoma","volume":"131","author":"Lim","year":"2018","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score 3, high-risk Hodgkin lymphoma: First results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"HD2000 Gruppo Italiano per lo Studio dei Limfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Limfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 Trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials","volume":"9","author":"Carde","year":"2020","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: A systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12094-020-02483-8","article-title":"ABVD and BEACOPP regimens\u2019 effects on fertility in young males with Hodgkin lymphoma","volume":"23","author":"Amin","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): A secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"ref_19","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin\u2019s disease","volume":"91","author":"Gallamini","year":"2006","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kanoun, S., Rossi, C., and Casanovas, O. (2018). [18F]FDG-PET\/CT in Hodgkin lymphoma: Current usefulness and perspectives. Cancers, 10.","DOI":"10.3390\/cancers10050145"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: Long-term results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: Final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: Final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: Safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3745\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:34:54Z","timestamp":1760164494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":35,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13153745"],"URL":"https:\/\/doi.org\/10.3390\/cancers13153745","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]}}}